AZ’ triple combo hits endpoint in COPD trial
admin 28th August 2019 Uncategorised 0Breztri Aerosphere – formerly known as PT010 – showed a 52% reduction in exacerbations. More: AZ’ triple combo hits endpoint in COPD trial Source: News
read more
Breztri Aerosphere – formerly known as PT010 – showed a 52% reduction in exacerbations. More: AZ’ triple combo hits endpoint in COPD trial Source: News
read moreThe clinical management of hypertension accounts for 12% of visits to primary care and up to £2.1 billion of healthcare expenditure. More: NICE updates hypertension guideline Source: News
read moreThe approval is based on data from the ELOQUENT-3 trial. More: Empliciti combo bags EU approval for multiple myeloma Source: News
read moreAt 48 weeks, 98% of patients treated with the drug were relapse free compared to 63% of patients receiving placebo. More: EU expands approval of Alexion’s Soliris Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals